HEC Pharm Awaits Fate As Novartis Petitions On US Gilenya Victory
Credit Suisse: High Probability Of 2024 Delay
Executive Summary
Novartis is sticking to its plan to continue fighting HEC Pharm in court, after it recently lost a key decision for its Gilenya (fingolimod) blockbuster treatment for multiple sclerosis.
You may also be interested in...
Viatris Slashes Full-Year Revenue Guidance By $800m
Viatris is committing to earlier EBITDA and free cash flow targets for 2022, although it now expects to lose a chunk of revenues for the full year amid severe and sustained foreign currency exposure.
Novartis Fends Off US Fingolimod Competition – For Now
The latest decision in US litigation with HEC Pharma over multiple sclerosis treatment Gilenya means that generics will be kept off the market for at least two years, according to originator Novartis.
Sole Challenger HEC Beaten On US Gilenya Patent
Imminent generic competition to Novartis’ Gilenya blockbuster in the US now seems impossible after a US district court held that the company’s dosage-regimen patent was both valid and infringed by HEC’s ANDA product. The Chinese firm may yet appeal the decision.